Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis
Top Cited Papers
Open Access
- 7 October 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (38), 3732-3739
- https://doi.org/10.1093/eurheartj/ehz698
Abstract
Drug-eluting devices (DED) represent a well-established therapy being widely used for endovascular revascularization (EVR) of peripheral vessels. Recent data indicate a two-fold increased long-term mortality in patients treated with paclitaxel-based DED. The subsequent safety concerns affected international regulatory authorities to enunciate several alerts for further application of DED. In 9.2 million insurants of the German BARMER Health Insurance, data on the application of paclitaxel-based drug-eluting stents (DES) and drug-coated balloons (DCB) were retrieved from their introduction on the market in 2007 until present. All patients with first EVR between 2007 and 2015 were indexed and followed until 31 December 2017. Each subsequently applied DES, DCB, bare-metal stent, and uncoated balloon was included in further analyses. Multivariable Cox regression analysis considered potential non-linear time-dependent hazard ratios (HRs) of DES and DCB over 11 years. We identified 64 771 patients who underwent 107 112 EVR procedures using 23 137 DED. Multivariable Cox regression analysis showed paclitaxel-based DES not to be associated with increased long-term mortality for over 11 years past application (all P > 0.057). DCB was associated with decreased long-term mortality for the first year past application (HR 0.92; P < 0.001), and indifferent correlation in the years thereafter (all P > 0.202). Our real-world analysis showed no evidence for increased mortality associated with paclitaxel-based DED for over 11 years.Funding Information
- Bayer
- Pfizer
This publication has 22 references indexed in Scilit:
- Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherenceEuropean Heart Journal, 2015
- The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal RevascularizationJACC: Cardiovascular Interventions, 2014
- Drug-Eluting Balloon in Peripheral Intervention for the Superficial Femoral ArteryJACC: Cardiovascular Interventions, 2013
- Recent trends in morbidity and in-hospital outcomes of in-patients with peripheral arterial disease: a nationwide population-based analysisEuropean Heart Journal, 2013
- Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal AngioplastyCirculation: Cardiovascular Interventions, 2012
- Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal DiseaseCirculation: Cardiovascular Interventions, 2011
- First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive diseaseJournal of Vascular Surgery, 2011
- Drug-Eluting Stents: More Dollars Than Sense?JACC: Cardiovascular Interventions, 2009
- Local Delivery of Paclitaxel to Inhibit Restenosis during Angioplasty of the LegThe New England Journal of Medicine, 2008
- Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen LossCirculation, 2006